Rapport Therapeutics (RAPP) Total Liabilities (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Total Liabilities of $26.1 million for Q1 2026, up 60.85% year-over-year from $16.2 million in Q1 2025, and down 6.09% quarter-over-quarter from $27.8 million in Q4 2025.
Rapport Therapeutics (RAPP) Total Liabilities (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Total Liabilities for 4 consecutive years, with $26.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 60.85% year-over-year to $26.1 million; the TTM figure through Mar 2026 stood at $26.1 million (up 60.85% YoY), while the FY2025 annual figure was $27.8 million, up 192.22% from the prior year.
- Total Liabilities retreated to $26.1 million in Q1 2026 per RAPP's latest filing, from $27.8 million in the prior quarter.
- Across five years, Total Liabilities topped out at $27.8 million in Q4 2025 and bottomed at $8.0 million in Q3 2024.
- Historically, Total Liabilities has averaged $17.4 million across 4 years, with a median of $16.2 million in 2025.
- Annual changes were most pronounced in 2024 — Total Liabilities tumbled 34.35% — and 2025, when it jumped 195.22%.
- Rapport Therapeutics' Total Liabilities stood at $14.5 million in 2023, then slumped by 34.35% to $9.5 million in 2024, then jumped by 192.22% to $27.8 million in 2025, then declined by 6.09% to $26.1 million in 2026.
- Business Quant data shows RAPP's Total Liabilities at $26.1 million in Q1 2026, $27.8 million in Q4 2025, and $23.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | 36.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.06 Mn |
| Mar 31, 2026 | 26.09 Mn |
| Dec 31, 2025 | 27.78 Mn |
| Sep 30, 2025 | 23.71 Mn |
| Jun 30, 2025 | 21.98 Mn |
| Mar 31, 2025 | 16.22 Mn |
| Dec 31, 2024 | 9.51 Mn |
| Sep 30, 2024 | 8.03 Mn |
| Jun 30, 2024 | 9.21 Mn |
| Dec 31, 2023 | 14.48 Mn |